Anti-KRAS binding proteins
View Patent ↗The present disclosure provides anti-KRAS antibodies, and antigen-binding fragments thereof. In certain embodiments, the anti-KRAS antibodies or fragments thereof, are used for the treatment of cancer.
1. An anti-KRAS antibody, or an antigen-binding fragment thereof, comprising:
(a) a heavy chain variable domain comprising the sequence of SEQ ID NO: 33 and a light chain variable domain comprising the sequence of SEQ ID NO: 34;
(b) a heavy chain variable domain comprising the sequence of SEQ ID NO: 63 and a light chain variable domain comprising the sequence of SEQ ID NO: 64;
(c) a heavy chain variable domain comprising the sequence of SEQ ID NO: 53 and a light chain variable domain comprising the sequence of SEQ ID NO: 54; or
(d) a heavy chain variable domain comprising the sequence of SEQ ID NO: 39 and a light chain variable domain comprising the sequence of SEQ ID NO: 40.
2. The anti-KRAS antibody or antigen-binding fragment thereof of claim 1 , comprising the heavy chain variable domain comprising the sequence of SEQ ID NO: 33 and the light chain variable domain comprising the sequence of SEQ ID NO: 34.
3. The anti-KRAS antibody or antigen-binding fragment thereof of claim 1 , comprising the heavy chain variable domain comprising the sequence of SEQ ID NO: 63 and the light chain variable domain comprising the sequence of SEQ ID NO: 64.
4. The anti-KRAS antibody or antigen-binding fragment thereof of claim 1 , comprising the heavy chain variable domain comprising the sequence of SEQ ID NO: 53 and the light chain variable domain comprising the sequence of SEQ ID NO: 54.
5. The anti-KRAS antibody or antigen-binding fragment thereof of claim 1 , comprising the heavy chain variable domain comprising the sequence of SEQ ID NO: 39 and the light chain variable domain comprising the sequence of SEQ ID NO: 40.
6. The anti-KRAS antibody of claim 1 , wherein the antibody is a human antibody and/or an IgG antibody.
7. The anti-KRAS antigen-binding fragment of claim 1 , wherein the antigen-binding fragment is a Fab fragment or an scFv.
8. The anti-KRAS antibody or antigen-binding fragment thereof of claim 1 , which is conjugated to an intracellular delivery compound.
9. A pharmaceutical composition comprising the anti-KRAS antibody or antibody fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
10. A method for treating a subject having cancer that expresses KRAS comprising administering the anti-KRAS antibody or antigen-binding fragment thereof of claim 1 to the subject.
11. The method of claim 10 , wherein the cancer is a cancer associated with a KRAS mutation.
12. The method of claim 11 , wherein the KRAS mutation is G12D mutation.
13. The method of claim 10 , wherein the cancer is pancreatic cancer, lung cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, colorectal cancer, leiomyoma, leiomyosarcoma, glioma, glioblastoma, esophageal cancer, liver cancer, kidney cancer, stomach cancer, colon cancer, cervical cancer, uterine cancer, liver cancer, or a hematological cancer.
14. A nucleic acid encoding an anti-KRAS antibody, or an antigen-binding fragment thereof, comprising:
(a) a heavy chain variable domain comprising the sequence of SEQ ID NO: 33 and a light chain variable domain comprising the sequence of SEQ ID NO: 34;
(b) a heavy chain variable domain comprising the sequence of SEQ ID NO: 63 and a light chain variable domain comprising the sequence of SEQ ID NO: 64;
(c) a heavy chain variable domain comprising the sequence of SEQ ID NO: 53 and a light chain variable domain comprising the sequence of SEQ ID NO: 54; or
(d) a heavy chain variable domain comprising the sequence of SEQ ID NO: 39 and a light chain variable domain comprising the sequence of SEQ ID NO: 40.
15. A vector comprising the nucleic acid of claim 14 .
16. A host cell comprising the nucleic acid of claim 14 or a vector comprising said nucleic acid.
17. An anti-KRAS antibody, or an antigen-binding fragment thereof, comprising:
(a) a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 171, 172, and 173, and a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 174, 175, and 176;
(b) a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 261, 262, or 263, and a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 264, 265, and 266;
(c) a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 231, 232, and 233, and a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 234, 235, and 236; or
(d) a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 189, 190, and 191, and a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 192, 193, and 194.
18. The anti-KRAS antibody or antigen-binding fragment thereof of claim 17 , wherein the anti-KRAS antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 189, 190, and 191, and a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 192, 193, and 194.
19. The anti-KRAS antibody or antigen-binding fragment thereof of claim 17 , wherein the anti-KRAS antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 33 and a light chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 34;
(b) a heavy chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 63 and a light chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 64;
(c) a heavy chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 53 and a light chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 54; or
(d) a heavy chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 39 and a light chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 40.
20. The anti-KRAS antibody or antigen-binding fragment thereof of claim 17 , wherein the anti-KRAS antibody or antigen-binding fragment thereof comprises:
a heavy chain variable domain comprising a heavy chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 189, 190, and 191;
a light chain variable domain comprising a light chain CDR set (CDR1, CDR2, and CDR3) of the sequences of SEQ ID NO: 192, 193, and 194;
a heavy chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 39; and
a light chain variable domain comprising a sequence with at least 95% identity to SEQ ID NO: 40.